INCREDB ID : 438
Home >> Investigator Page Previous      Next
Gopal Kundu,
Scientist F 
 
National Centre for Cell Science
NCCS Complex, Pune University Campus
Ganeshkhind
Pune - 411 007   
Maharashtra   
 
E-mail: kundu@nccs.res.in, gopalkundu@hotmail.com
Phone: +91-020-25708103, 25708000
 
URL: http://www.nccs.res.in/gck.html#Memberships
 
Area of Specialization:
Oncology
Research Summary:
Regulation of Gene Expression, Signal Transduction, Extracellular Matrix, Tumor Biology and Angiogenesis
 
Publications:
1.Thorat, D., Sahu, A., Behera, R., Lohite, K., Deshmukh, S., Mane, A., Karnik, S., Doke, S. and Kundu, G. C.  Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology Letters. 2013.  6, 1559-1564. [PubMed]
2.Haldar, S., Kumar, S., Kolet, S. P., Patil, H. S., Kumar, D., Kundu, G. C. and Thulasiram, H. V.  One-pot fluorescent labeling protocol for complex hydroxylated bioactive natural products. The Journal of Organic Chemistry. 2013.  78, 10192-10202. [PubMed]
3.Kumar, S., Sharma, P., Kumar, D., Chakraborty, G., Gorain, M. and Kundu, G. C.  Functional characterization of stromal osteopontin in melanoma progression and metastasis. PloS One. 2013.  8, e69116. [PubMed]
4.Syed, A., Saraswati, S., Kundu, G. C. and Ahmad, A.  Biological synthesis of silver nanoparticles using the fungus Humicola sp. and evaluation of their cytoxicity using normal and cancer cell lines. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy. 2013.  114, 144-147. [PubMed]
5.Panda, J. J., Kaul, A., Kumar, S., Alam, S., Mishra, A. K., Kundu, G. C. and Chauhan, V. S.  Modified dipeptide-based nanoparticles: vehicles for targeted tumor drug delivery. Nanomedicine. 2013.  8, 1927-1942. [PubMed]
6.Chakraborty, G., Kumar, S., Mishra, R., Patil, T. V. and Kundu, G. C.  Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PloS One. 2012.  7, e33633. [PubMed]
7.Ahmed, M., Behera, R., Chakraborty, G., Jain, S., Kumar, V., Sharma, P., Bulbule, A., Kale, S., Kumar, S., Mishra, R., Raja, R., Saraswati, S., Kaur, R., Soundararajan, G., Kumar, D., Thorat, D., Sanyal, M., Ramdasi, A., Ghosh, P. and Kundu, G. C.  Osteopontin: a potentially important therapeutic target in cancer. Expert Opinion On Therapeutic Targets. 2011.  15, 1113-1126. [PubMed]
8.Prakash, M., Kale, S., Ghosh, I., Kundu, G. C. and Datta, K.  Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin alpha(v)beta(3) interaction. Cellular Signalling. 2011.  23, 1563-1577. [PubMed]
9.Bulbule, A., Saraswati, S. and Kundu, G. C.  Status of research on matrix metalloproteinases (MMPs) in India. Expert Opinion On Therapeutic Targets. 2011.  15, 671-675. [PubMed]
10.Pradhan, S. J., Mishra, R., Sharma, P. and Kundu, G. C.  Quercetin and sulforaphane in combination suppress the progression of melanoma through the down-regulation of matrix metalloproteinase-9. Experimental and Therapeutic Medicine. 2010.  1, 915-920. [PubMed]
11.Kumar, V., Behera, R., Lohite, K., Karnik, S. and Kundu, G. C.  p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Research. 2010.  70, 10381-10391. [PubMed]
12.Sharma, P., Kumar, S. and Kundu, G. C.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Molecular Cancer. 2010.  9, 178. [PubMed]
13.Singh, J. P., Tamang, S., Rajamohanan, P. R., Jima, N. C., Chakraborty, G., Kundu, G. C., Gaikwad, S. M. and Khan, M. I.  Isolation, structure, and functional elucidation of a modified pentapeptide, cysteine protease inhibitor (CPI-2081) from Streptomyces species 2081 that exhibit inhibitory effect on cancer cell migration. Journal of Medicinal Chemistry. 2010.  53, 5121-5128. [PubMed]
14.Ahmed, M. and Kundu, G. C.  Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Molecular Cancer. 2010.  9, 101. [PubMed]
15.Behera, R., Kumar, V., Lohite, K., Karnik, S. and Kundu, G. C.  Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis. 2010.  31, 192-200. [PubMed]
16.Seth, D., D'Souza, E., Apte, M., Mari, M., Dooley, S., Neuman, M., Haber, P. S., Kundu, G. C., Darwanto, A., de, V., Vonlaufen, A., Xu, Z., Phillips, P., Yang, S., Goldstein, D., Pirola, R. M., Wilson, J. S., Moles, A., Fernandez, A., Colell, A., Garcia-Ruiz, C., Fernandez-Checa, J. C., Meyer, C. and Meindl-Beinker, N. M.  Alcohol, signaling, and ECM turnover. Alcoholism, Clinical and Experimental Research. 2010.  34, 4-18. [PubMed]
17.Jain, S., Chakraborty, G., Raja, R., Kale, S. and Kundu, G. C.  Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Research. 2008.  68, 7750-7759. [PubMed]
18.Chakraborty, G., Jain, S., Kale, S., Raja, R., Kumar, S., Mishra, R. and Kundu, G. C.  Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Molecular Medicine Reports. 2008.  1, 641-646. [PubMed]
19.Chakraborty, G., Jain, S., Patil, T. V. and Kundu, G. C.  Down-regulation of osteopontin attenuates breast tumour progression in vivo. Journal of Cellular and Molecular Medicine. 2008.  12, 2305-2318. [PubMed]
20.Chakraborty, G., Jain, S. and Kundu, G. C.  Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Research. 2008.  68, 152-161. [PubMed]
21.Rangaswami, H. and Kundu, G. C.  Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncology Reports. 2007.  18, 909-915. [PubMed]
22.Chakraborty, G., Jain, S., Behera, R., Ahmed, M., Sharma, P., Kumar, V. and Kundu, G. C.  The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Current Molecular Medicine. 2006.  6, 819-830. [PubMed]
23.Jain, S., Chakraborty, G., Bulbule, A., Kaur, R. and Kundu, G. C.  Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opinion On Therapeutic Targets. 2007.  11, 81-90. [PubMed]
24.Jain, S., Chakraborty, G. and Kundu, G. C.  The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Research. 2006.  66, 6638-6648. [PubMed]
25.Rangaswami, H., Bulbule, A. and Kundu, G. C.  Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation. Glycoconjugate Journal. 2006.  23, 221-232. [PubMed]
26.Chakraborty, G., Rangaswami, H., Jain, S. and Kundu, G. C.  Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. The Journal of Biological Chemistry. 2006.  281, 11322-11331. [PubMed]
27.Rangaswami, H., Bulbule, A. and Kundu, G. C.  Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biology. 2006.  16, 79-87. [PubMed]
28.Das, R., Philip, S., Mahabeleshwar, G. H., Bulbule, A. and Kundu, G. C.  Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005.  57, 441-447. [PubMed]
29.Rangaswami, H., Bulbule, A. and Kundu, G. C.  JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. The Journal of Biological Chemistry. 2005.  280, 19381-19392. [PubMed]
30.Philip, S., Bulbule, A. and Kundu, G. C.  Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate Journal. 2004.  21, 429-441. [PubMed]
31.Rangaswami, H., Bulbule, A. and Kundu, G. C.  Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. The Journal of Biological Chemistry. 2004.  279, 38921-38935. [PubMed]
32.Sandbhor, U., Kulkarni, P., Padhye, S., Kundu, G., Mackenzie, G. and Pritchard, R.  Antimelanomal activity of the copper(II) complexes of 1-substituted 5-amino-imidazole ligands against B16F10 mouse melanoma cells. Bioorganic & Medicinal Chemistry Letters. 2004.  14, 2877-2882. [PubMed]
33.Das, R., Mahabeleshwar, G. H. and Kundu, G. C.  Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. The Journal of Biological Chemistry. 2004.  279, 11051-11064. [PubMed]
34.Mahabeleshwar, G. H., Das, R. and Kundu, G. C.  Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. The Journal of Biological Chemistry. 2004.  279, 9733-9742. [PubMed]
35.Mahabeleshwar, G. H. and Kundu, G. C.  Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation. The Journal of Biological Chemistry. 2003.  278, 52598-52612. [PubMed]
36.Das, R., Mahabeleshwar, G. H. and Kundu, G. C.  Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. The Journal of Biological Chemistry. 2003.  278, 28593-28606. [PubMed]
37.Takada, Y., Mukhopadhyay, A., Kundu, G. C., Mahabeleshwar, G. H., Singh, S. and Aggarwal, B. B.  Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. The Journal of Biological Chemistry. 2003.  278, 24233-24241. [PubMed]
38.Mahabeleshwar, G. H. and Kundu, G. C.  Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells. The Journal of Biological Chemistry. 2003.  278, 6209-6221. [PubMed]
39.Philip, S. and Kundu, G. C.  Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. The Journal of Biological Chemistry. 2003.  278, 14487-14497. [PubMed]
Grant Support:
Project Title Role Funding Agency Sanction Number Sanction Date
Role of splice variants, secretory and intracellular OPN in regulation of stroma-tumor interaction leading to tumor angiogenesis, tumor cell invasion and metastasis. Role of OPN and αvβ3 integrin in epithelial to mesenchymal transition and its correlation to tumor growth and metastasis
Studies on peptide nanoparticle-mediated drug/siRNA delivery to tumor vasculature regulates tumor growth and angiogenesis using in vitro and in vivo model and it's analysis by In Vivo Imaging System (IVIS)
Development of novel diagnostic and prognostic clinical biomarkers in breast cancer

 

 
 
Honors and Awards
::
Prof. R.C. Shah Memorial Lecture Award, The Indian Science Congress Association, 2004
::
National Bioscience Award for career development, Department of Biotechnology, New Delhi, 2003
::
Shanti Swarup Bhatnagar Prize in Biological Sciences, Council of Scientific and Industrial Research
Member
::
Member of New York Academy of Sciences, USA
::
Life member of Indian Society of Cell Biology
::
Member of Molecular Immunology Forum
::
Fellow of the National Academy of Sciences, India
::
Member of Guha Research Conference
  Last modified on : Dec 1, 2013
India Cancer Research Database has been developed by the Institute of Bioinformatics with funding from the Department of Biotechnology, Government of India.